The latest cancer drugs news
Browsing: Cancer Drug News
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib with…
Cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment
An important discovery from the NCI-MATCH precision medicine initiative published in Clinical Cancer Research, a…
Researchers edge closer to delivering personalised medicine to cancer patients
Chemotherapy can save lives, but often a cancer patient may be resistant to their prescribed…
Study proposes streamlined approach to developing cancer drugs
Drug discovery can be a frustrating process of trial and error. Scientists using fragment-based drug…
Clues to cancer drug’s deadly side effects could make it safer
For some leukaemia patients, the only potential chemotherapy option is a drug that also carries…
Elenagen delays disease progression
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has…
‘Protein sandwich’ could transform cancer drug discovery
A breakthrough class of molecular glue identified at the University of Dundee, Scotland, could pave…
FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III-IVA cervical cancer
On January 12, 2024, the Food and Drug Administration approved pembrolizumab with chemoradiotherapy (CRT) for patients…
European Medicines Agency is looking at approving lazertinib, in combination with amivantamab, for the first-line treatment of patients with EGFR-mutated NSCLC
The Janssen Pharmaceutical Companies of Johnston & Johnson announced the submission of a marketing authorisation application…
FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib for adults…